Catalent (CTLT) Shares are Down -0.82%

Catalent (CTLT) has risen sharply, recording gains of 8.11% in the past 4 weeks. However, the stock has corrected -0.82% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 5.49% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Catalent (NYSE:CTLT): The stock opened at $25.62 on Friday but the bulls could not build on the opening and the stock topped out at $25.71 for the day. The stock traded down to $25.25 during the day, due to lack of any buying support eventually closed down at $25.33 with a loss of -0.59% for the day. The stock had closed at $25.48 on the previous day. The total traded volume was 422,458 shares.

The stock has recorded a 20-day Moving Average of 3.21% and the 50-Day Moving Average is 4.27%. Catalent, Inc. is up 3.51% in the last 3-month period. Year-to-Date the stock performance stands at 1.2%.

Catalent (CTLT) : 5 Wall Street analysts covering Catalent (CTLT) believe that the average level the stock could reach for the short term is $26.5. The maximum price target given is $31 and the minimum target for short term is around $23, hence the standard deviation is calculated at $2.87.


Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *